

Cite this: *Chem. Sci.*, 2017, **8**, 6313

Full color palette of fluorescent D-amino acids for *in situ* labeling of bacterial cell walls†

Yen-Pang Hsu, Jonathan Rittichier, Erkin Kuru, Jacob Yablonowski, a Erick Pasciak, Srinivas Tekkam, Edward Hall, b Brennan Murphy, b Timothy K. Lee, c Ethan C. Garner, d Kerwyn Casey Huang, e Yves V. Brun*^f and Michael S. VanNieuwenhze *^{ab}

Fluorescent D-amino acids (FDAs) enable efficient *in situ* labeling of peptidoglycan in diverse bacterial species. Conducted by enzymes involved in peptidoglycan biosynthesis, FDA labeling allows specific probing of cell wall formation/remodeling activity, bacterial growth and cell morphology. Their broad application and high biocompatibility have made FDAs an important and effective tool for studies of peptidoglycan synthesis and dynamics, which, in turn, has created a demand for the development of new FDA probes. Here, we report the synthesis of new FDAs, with emission wavelengths that span the entire visible spectrum. We also provide data to characterize their photochemical and physical properties, and we demonstrate their utility for visualizing peptidoglycan synthesis in Gram-negative and Gram-positive bacterial species. Finally, we show the permeability of FDAs toward the outer-membrane of Gram-negative organisms, pinpointing the probes available for effective labeling in these species. This improved FDA toolkit will enable numerous applications for the study of peptidoglycan biosynthesis and dynamics.

Received 22nd April 2017
Accepted 6th July 2017

DOI: 10.1039/c7sc01800b
rsc.li/chemical-science

Introduction

The peptidoglycan (PG) cell wall is a macromolecular polymer of glycan strands crosslinked by short peptides that surrounds the cytoplasmic membrane of most bacteria.^{1,2} The cell wall serves as a rigid layer that protects bacteria from environmental stresses and dictates cell shape throughout their life cycle. Elucidating the mechanisms by which PG biosynthesis results in robust morphogenesis is a major challenge in microbiology,

and inhibition of PG synthesis has proven a valuable strategy for the identification and development of antibiotics.

Prior efforts directed at visualizing the sites of nascent PG growth have relied on fluorescently modified antibiotics or fluorescent lectins such as wheat germ agglutinin.^{3–6} We recently reported a new strategy that utilized a novel set of metabolic probes, fluorescent D-amino acids (FDAs), for *in situ* PG labeling/monitoring.^{7–9} This approach relies on the inherent promiscuity of the PG biosynthetic pathway to incorporate small molecules conjugated to a D-amino acid backbone into the sites of new PG synthesis. This promiscuity is thought to be the result of a D-amino acid exchange reaction conducted by ubiquitous transpeptidases, penicillin-binding proteins (PBPs) and/or L,D-transpeptidases (Ldts) (Fig. 1A).^{10–12} The FDA technology has demonstrated efficacy in diverse bacterial species, enabling spatiotemporal tracking of PG synthesis and modification in real-time and in live bacterial cells.^{13–24}

To further enhance the utility of FDAs in a variety of labeling applications, we report the design and synthesis of a new set of FDA probes that cover five spectrally separable colors of the optical spectrum ranging from violet to far-red (Fig. 1B). Additionally, we provide photochemical, physical, and biological characterizations that will serve as a valuable resource when choosing the optimal FDA for a labeling experiment of interest.

^aDepartment of Molecular and Cellular Biochemistry, Indiana University, Bloomington, IN 47405, USA. E-mail: mvannie@indiana.edu

^bDepartment of Chemistry, Indiana University, Bloomington, IN 47405, USA

^cDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA

^dMolecular and Cellular Biology (FAS) Center for Systems Biology, Harvard University, Cambridge, Massachusetts 02138, USA

^eDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA

^fDepartment of Biology, Indiana University, Bloomington, IN 47405, USA. E-mail: ybrun@indiana.edu

† Electronic supplementary information (ESI) available. See DOI: [10.1039/c7sc01800b](https://doi.org/10.1039/c7sc01800b)

‡ These authors contributed equally.

§ Current address: Department of Genetics, Harvard Medical School, Boston, MA 021157, USA.

¶ Current address: School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA 30332, USA.

|| Current address: Department of Chemistry, Hanover College, Hanover, IN 47243, USA.





Fig. 1 PBP-facilitated FDAA incorporation mechanism and novel FDAA structures. (A) Comparison of the transpeptidation reaction performed by penicillin-binding proteins (PBPs, top) and proposed mechanism of FDAA incorporation (bottom). The peptide-PBP intermediate (acyl donor) is attacked by the free amine of lysine in another peptide chain (acyl acceptor), which leads to cross-linking. FDAsAs mimic the acyl acceptor to interact with the peptide-PBP intermediate. (B) Structures of FDAsAs reported in this study.

Results and discussion

Design and synthesis of improved FDAsAs

A new FDAA should follow the basic design principles for biomolecular fluorescent probes: a “carrier” moiety to specifically bind to the target of interest (*i.e.*, a D-amino acid backbone), a fluorophore that emits light upon excitation, and a linker to join the two together.²⁵ Parameters defining an ideal fluorescent probe can be largely separated into two categories: (1) photochemical properties that determine the performance of probes in microscopy, such as excitation/emission spectra and brightness, and (2) physical properties that are related to molecular interactions between probes, their targets, and their surroundings, such as solubility and stability. Optimal labeling with probes such as FDAsAs relies on these properties, as well as appropriate labeling and imaging conditions required for a specific use/application.

FDAsAs are biocompatible, and their labeling provides a fluorescent readout of PG synthesis and remodeling activity.⁸ Combining FDAsAs with protein labels and/or fluorescent antibiotics and with super-resolution imaging technologies provides a powerful experimental approach to elucidate the spatiotemporal regulation necessary for robust bacterial growth and division.^{14,24} Sequential pulses with differently colored FDAsAs enable sub-cellular tracking of PG growth *via* “virtual time-lapse” microscopy that reveals the history of PG synthesis

and remodeling sites during an experiment as reported by the emission and detection of each color.^{9,14} Given the demonstrated utility of FDAA probes, we sought to expand the available FDAA color palette with probes possessing improved photochemical and/or physical properties, thereby further enhancing the utility of this valuable class of probes in various experimental applications.

The general synthetic strategy for FDAsAs is composed of three straightforward steps (Fig. 2A): (1) coupling of an N^z-protected-D-amino acid to an activated fluorophore, purchased in its pre-activated form or synthesized in-house (Table 1), (2) removal of the N^z protecting group, and (3) purification of the FDAA. The coupling reaction is usually carried out with an activated fluorophore and a D-amino acid with Boc/Fmoc-protected α -amine under basic conditions and at ambient temperature. Boc-deprotection is achieved by dissolving the coupling product in a mixture of dichloromethane (DCM) and trifluoroacetic acid (TFA) at a 1 : 1 ratio and stirring at ambient temperature for approximately 2 h. An Fmoc-protecting group can be removed by suspension of the coupling product in DCM followed by treatment with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). The crude FDAA product(s) can be purified using reverse-phase high-performance liquid chromatography (HPLC, 1 : 1 acetonitrile/water).

In an effort to develop a probe to expand FDAsAs into the violet-to-blue region of the visible spectrum, we first attempted




Fig. 2 Synthesis scheme and spectra of FDAA. (A) FDAA synthesis is achieved by coupling conjugation-activated fluorophores with 3-amino-D-alanine (3-aminopropionic acid) or D-lysine. (B and C) Excitation (B) and emission (C) spectra of FDAA in phosphate-buffer saline (1× PBS) at pH 7.4. Absorbance and fluorescence intensity were normalized to their maximum values.

Table 1 Spectroscopic data and synthesis information of the FDAA in the study

Dye (emission)	MW ^a (daltons)	Ex. Max. ^b (nm)	Em. Max. ^b (nm)	ϵ^c ($M^{-1} \text{ cm}^{-1}$)	Φ^c	Fluorophore	Commercially-available pre-activated fluorophore
Violet-to-blue							
AF ₃₅₀ DL	441	348	448	19 000	NA	Alexa Fluor® 350	NHS-ester (ThermoFisher)
HADA	292	404	450	36 700	NA	7-Hydroxycoumarin-3-carboxylic acid	NHS-ester (Sigma-Aldrich)
Green							
sBADA	457	490	510	49 000	NA	Sulfonated BODIPY	Not available
BADA	378	502	518	91 000 (ref. 47)	0.9491000 (ref. 47)	BODIPY	NHS-ester (ThermoFisher)
Atto ₄₈₈ ADA	674	502	525	90 000	0.8	Atto 488	NHS-ester (Sigma-Aldrich)
Green-to-yellow							
YADA	489	426	535	2 420 091 000 (ref. 47)	0.2191000 (ref. 47)	Lucifer yellow	Anhydride form (Setareh)
Yellow-to-orange							
TADA	517	554	580	9 500 091 000 (ref. 47)	0.6891000 (ref. 47)	TAMRA	NHS-ester (ThermoFisher)
Cy _{3B} ADA	647	558	574	13 000 091 000 (ref. 47)	0.6791000 (ref. 47)	Cy TM 3B	NHS-ester (GE)
Red							
Atto ₆₁₀ ADA	463	614	631	15 000 091 000 (ref. 47)	0.791000 (ref. 47)	Atto 610	NHS-ester (Sigma-Aldrich) ^d

^a Values for unsalted FDAA. The molecular weight of conjugated salt was not included. ^b FDAA spectra were measured in PBS buffer at 1× pH 7.4 (containing 0.1% DMSO). ^c Extinction coefficient (ϵ) or quantum yield (Φ) of fluorophores used for FDAA synthesis. Values are from the dye manufacturer, except as noted from ref. 47. NA: not available. ^d Synthesis of Atto₆₁₀ADA using commercially available Atto₆₁₀ NHS ester resulted in a less stable product (data not shown). We modified the structure of the linker moiety, producing stable Atto₆₁₀ADA. Please note that the commercially available Atto₆₁₀ NHS ester contains a butyric linker. See ESI for detailed synthesis scheme.

to couple an activated Alexa Flour 350 dye with 3-Amino-D-alanine. The chemical instability of the product obtained after the deprotection reaction (data not shown) prompted us to use D-lysine instead, which resulted in the stable AF₃₅₀DL (Alexa Flour® 350 D-Lysine) (Table 2 and Fig. 2B). For green-emission probes, in addition to previously reported BADA (BODIPY-FL 3-amino-D-alanine), we further prepared sBADA (sulfonated BODIPY-FL 3-amino-D-alanine) and Atto₄₈₈ADA (Atto 488 3-amino-D-alanine) from sulfonated BODIPY-FL and Atto 488 dye, respectively.^{26,27} For a new green-to-yellow emitting probe that would be spectrally separable from green FDAA, we

used Lucifer yellow to construct YADA (Lucifer Yellow 3-amino-D-alanine). For yellow-to-orange emission probe, in addition to TADA/TDL (TAMRA 3-amino-D-alanine/D-Lysine),¹⁵ we prepared Cy_{3B}ADA (Cy3B 3-amino-D-alanine) from CyTM3B. Finally, we synthesized a red-to-far-red FDAA, Atto₆₁₀ADA (Atto 610 3-amino-D-alanine), based on the reported Atto 610 dye.

Photochemical properties and labeling with new FDAA

In fluorescence microscopy, the separation of excitation and emission wavelengths of a probe is achieved by selecting filters to

Table 2 Photochemical and physical characterization of the FDAs in this study

Dye (emission)	Ex. filter wavelength (nm)	Em. filter wavelength (nm)	Water-solubility ^{a,b}	Photo-stability ^{a,c}	Thermostability ^{a,d}		
					5 min	2 h	24 h
Violet-to-blue							
AF ₃₅₀ DL	395/25	435/26	+++	+++	>99	>99	98.9
HADA	395/25	435/26	+++	+	>99	>99	96.9
Green							
sBADA	470/24	510/40	+++	++	>99	>99	98.5
BADA	470/24	510/40	+	++	>99	>99	92.2
Atto ₄₈₈ ADA	470/24	510/40	+++	+++	>99	>99	98.3
Green-to-yellow							
YADA	395/25	510/40	+++	+++	>99	>99	>99
Yellow-to-orange							
TADA	550/15	595/40	+++	+++	>99	>99	>99
Cy _{3B} ADA	550/15	595/40	+++	++	>99	>99	>99
Red							
Atto ₆₁₀ ADA	640/30	705/72	++	+++	>99	98.2	21.7

^a Data were measured in PBS buffer at pH 7.4 (containing 0.1% DMSO). ^b FDAs were assigned “+++”, “++”, or “+” if the measured distribution coefficient $\log D_{7.4}$ was <-1 , between -1 and 0 , or >0 , respectively. ^c FDAs were assigned “+++”, “++”, or “+” if the measured exponential decay coefficient was <0.1 , $0.1-1$, or >1 , respectively. ^d The data represent signal retention of absorbance of dye solution incubated at 37 °C for 5 min, 2 h, or 24 h, compared to the corresponding initial value.

block or pass wavelengths specific for that probe. Under physiological conditions (in 1× phosphate-buffer saline, or PBS, at pH 7.4), AF₃₅₀DL (maximum $\lambda_{\text{ex/em}} = 348/448$ nm) is ideally excited by ultraviolet light (~ 350 nm). However, AF₃₅₀DL can be partially excited by a visible violet light source (395/25 nm) and imaged using a typical blue filter set (435/26 nm, Tables 2, S3 and Fig. S1†). Thus, AF350DL can be used as an alternative of HADA (maximum $\lambda_{\text{ex/em}} = 400/450$ nm), a previously published blue FDA. BADA (maximum $\lambda_{\text{ex/em}} = 502/518$ nm), sBADA (maximum $\lambda_{\text{ex/em}} = 490/510$ nm) and Atto₄₈₈ADA (maximum $\lambda_{\text{ex/em}} = 502/525$ nm) can be visualized using a blue light source (470/24 nm) and a green emission filter (510/40 nm, Table 2). By comparison, YADA (maximum $\lambda_{\text{ex/em}} = 426/535$ nm) has a shorter excitation wavelength but a red-shifted and wider emission spectrum. The large Stokes shift and wider excitation/emission spectra of YADA enable it to be distinguished from other blue-, green-, and red-emitting FDAs when appropriate microscopy settings are used. For example, YADA can be excited by a violet light source and detected by a green filter (or even by a red filter if necessary). Similar to the published yellow-to-orange-emitting TADA (maximum $\lambda_{\text{ex/em}} = 554/580$ nm), Cy_{3B}ADA (maximum $\lambda_{\text{ex/em}} = 558/574$ nm) can be excited by green light (550/15 nm) and visualized by a red filter (595/40 nm, Table 2). Finally, Atto₆₁₀ADA (maximum $\lambda_{\text{ex/em}} = 614/631$ nm) can be excited by a red light source (640/30 nm) and detected through use of a far-red filter (705/72 nm). The extinction coefficient (ϵ) and quantum yield (Φ) of fluorophores used for FDA synthesis are shown in Table 1. Since no significant changes in the excitation and emission spectra were observed after these fluorophores were coupled to D-amino acids, we expect the corresponding FDAs to retain similar extinction coefficients and quantum yields.

Two commonly utilized FDA labeling strategies differ from each other in their respective labeling times. Long-pulse labeling

experiments usually result in labeling of the whole cell, while short-pulse labeling enables visualization of the sites of transpeptidation activity during the pulse period. We confirmed the incorporation of our new FDAs into PG by growing cells of the Gram-negative *Escherichia coli* and Gram-positive *Bacillus subtilis*, two evolutionarily distant model organisms, in the presence of these molecules for several generations (Fig. S2†). No toxic effects were observed. In addition, pre-fixed cells were not labeled, suggestive of metabolic incorporation of these FDAs (Fig. S3†). TADA and Atto₆₁₀ADA labeling in pre-fixed *E. coli* showed non-specific signal inside the cell (Fig. S3†). This might result from the trapped probes inside the cells after fixation which changes outer-membrane permeability toward FDAs. Indeed, we also observed increased background intensity of FDAs upon ethanol fixation in other Gram-negative species, such as *C. crescentus* (data not shown). Thus, control experiments using live cells were highly recommended if one needs to do cell fixation. Labeling using the L-isomer of TADA (TALA) showed no signal in live *E. coli* cells (data not shown), confirming the metabolic incorporation of the probe.

The addition of more distinct colors allows for increased spatiotemporal resolution of a virtual time-lapse labeling experiment, as seen for labeling of the polar-growing and branching bacterium *Streptomyces venezuelae* with four FDAs (Fig. 3A). *S. venezuelae* cells were successively pulsed with Atto₄₈₈ADA (3 h), Cy_{3B}ADA (15 min), AF₃₅₀DL (15 min), and Atto₆₁₀ADA (15 min). In this experiment, while the long-pulse labeling with Atto₄₈₈ADA is necessary to delineate the pattern of the oldest PG at the start of the experiment, the short pulses with three distinct FDAs resolved the polar, newer PG synthesis activity (Fig. 3A, white arrows) over a 45 min interval with a temporal resolution of 15 min per color.^{9,14} With appropriate adjustment to labeling and microscopy conditions, our






Fig. 3 Virtual time-lapse FDAA labeling. (A) *Streptomyces venezuelae* cells were sequentially labeled with Atto₄₈₈ADA (3 h), Cy_{3B}ADA (15 min), AF₃₅₀DL (15 min), and Atto₆₁₀ADA (15 min), and then fixed and imaged. Left: Phase-contrast; right: fluorescence. Scale bar: 5 μ m. White arrows point out new branches formed at different time points (oldest to newest: (a) to (c)). (B) *Lactococcus lactis* cells were sequentially labeled with Atto₆₁₀ADA (8 min), HADA (5 min), YADA (8 min), sBADA (5 min), and TADA (5 min), and then fixed and imaged. Left to right: Phase channel, Atto₆₁₀ADA, HADA, YADA, sBADA, TADA, and merged image. Scale bar: 1 μ m.

expanded FDAA toolkit now enables virtual time-lapse labeling with up to five colors, in which YADA can be distinguished from blue- and green-emission probes (Fig. 3B).

Improved physical properties of the new FDAs

FDAs decorate PG with high specificity that is endowed by the unique selectivity of the PG biosynthetic pathways for *D*-amino acids over their *L*-isomers. However, FDAs with low water solubility might result in non-specific staining of the cell membrane. We determined the water solubility of all FDAs in order to evaluate their potential for non-specific labeling. Specifically, with a given total FDA concentration, we performed extractions of FDAs in 1 \times PBS (pH 7.4) and 1-octanol and then measured the amount of FDA distributed in each solvent layer. These measurements were used to calculate the distribution coefficient, $\log D_{7.4}$, where a smaller value represents greater hydrophilicity.^{28,29} Our previous experience with various probes suggest that FDAs with $\log D_{7.4}$ values higher than 1 show a greater propensity for non-specific labeling. Each of the novel FDAs reported here had $\log D_{7.4}$ values less than 1 (Tables 2 and S1†). Labeling experiments in pre-fixed *B. subtilis* showed no significant signal, confirming that non-specific membrane labeling by these FDAs is minimal (Fig. S3†). The degree of non-specific labeling could also depend on the

species-specific composition of membranes and experimental conditions. Of all the FDAs, BADA has the lowest relative water solubility, which might compromise its overall utility due to non-specific labeling. This observation was the underlying motivation for preparation of the sulfonated form of BADA (sBADA), which displays significantly increased hydrophilicity. High hydrophilicity also simplifies the washing steps for cell labeling with aqueous buffers, which are required to minimize background fluorescence, and allows for use of higher FDA concentrations in aqueous solutions (e.g. growth medium), which is known to enhance the signal-to-background ratio favoring the incorporation reaction.⁹

Depending on the bacterial species and the goals of the labeling experiment, the FDA labeling duration and sample processing could range from minutes to days. Thus, in most cases, high FDA stability during labeling at physiological conditions is desired, especially for quantitative fluorescence experiments. We examined thermal stability of the FDAs by measuring the percentage of signal retention after an incubation in PBS (pH 7.4) at 37 °C for 5 min, 2 h, or 24 h. No significant signal reduction was observed for all the FDAs in short incubation times between 5 min and 2 h (Table 2). After 24 h of incubation, we observed a minimal signal decrease of <10% for most of the FDAs, suggesting that these probes exhibit high thermal stability for at least 1 day under our

experimental conditions. However, Atto₆₁₀ADA showed a significant signal reduction after 24 h of incubation, with 50% signal loss after 10 h of incubation in PBS (Fig. S4†). Thus, careful optimization and control experiments are required when using Atto₆₁₀ADA for long-pulse labeling and quantification, especially if the experiment exceeds \sim 10 h at 37 °C.

Because FDAs are non-toxic, they can be used for time-lapse microscopy. In a typical time-lapse experiment, the high photostability of a fluorescent probe is important as the probe gets regularly exposed to the excitation light.^{30–32} To evaluate the photostability of FDAs, we measured relative decay curves of fluorescence emission intensity for each FDAs at their emission maximum (λ_{em}) with continuous excitation at their corresponding excitation maximum (λ_{ex}) in *B. subtilis* samples labeled under long-pulse conditions. Fitting to an exponential curve enabled determination of the exponential decay coefficient (EDC) as a metric of FDA photostability, where a smaller EDC represents greater photostability (Tables 2 and S1†). Of all the FDAs, HADA is the most sensitive to prolonged light exposure (Fig. S5†). It has a relatively high EDC value of 1.186 and a fluorescence half-life of 0.5846 s under our experimental conditions. In contrast, the other blue-to-violet FDA, AF₃₅₀DL, has an EDC of 0.0497 and a fluorescence half-life of 13.950 s under the same conditions. Since HADA has also shown utility for acquiring three-dimensional structured illumination microscopy (3D-SIM) images,^{8,14} which require prolonged excitation from a powerful laser (Fig. S6†), we predict all the FDAs reported here will have sufficient photostability for most uses and applications. Furthermore, excitation-based phototoxicity could be a major issue for cell viability, especially in time-lapse microscopy experiments. Use of red-shifted TADA, Cy_{3B}ADA, and Atto₆₁₀ADA for such experiments addresses this problem,

because cells are tolerant to low-energy excitation light.^{31,33} Therefore, we conclude that the new FDAs reported here have improved photophysical properties for use in imaging applications that require prolonged excitation.

Outer membrane permeability of FDAs

The outer membrane (OM) of Gram-negative bacteria is an effective barrier that protects cells from toxins in the environment. Many antibiotics show low toxicity to Gram-negative species because the OM provides a permeability barrier that inhibits access to the periplasm and cytoplasm.³⁴ The OM also blocks the entry of larger fluorescent probes, resulting in lower labeling efficiency. Gram-negative cells import water-soluble materials through the OM *via* porins, a class of membrane proteins that serve as transport channels. Transport is limited by the size of porin channels as well as of the cargo: a molecular weight (MW) of \sim 600 g mol^{−1} was reported as the cargo cutoff size.^{35,36} The MW of FDAs reported here ranges from \sim 300 to \sim 700 g mol^{−1}. To investigate the OM permeability of the FDAs in a model Gram-negative species, we labeled wild type *E. coli* BW25113 with FDAs and measured the signal-to-background ratio (S/B) of the signal. HADA and YADA showed high labeling efficiency with S/B values >4 (Table 3). BADA, sBADA, and Atto₆₁₀ADA had S/B values between 2 and 4. AF₃₅₀DL, Atto₄₈₈ADA, TADA, and Cy_{3B}ADA had relatively low labeling efficiency in WT *E. coli*, with S/B values <2 .

These S/B values are relative and are dependent upon species/strain, labeling conditions, auto-fluorescence of cells, and microscopy settings. To quantify the barrier effect of the OM on each of these FDAs in *E. coli*, we compared FDA intensity between wild-type *E. coli* BW25113 and *E. coli* *imp4213*

Table 3 The relationship between the size of an FDA and its utility in a Gram-negative bacterium

Dye (emission)	MW g mol ^{−1} (daltons)	S/B ratio in <i>E. coli</i> ^a	OM blocking factor ^b
Violet-to-blue			
AF ₃₅₀ DL	441	+	4.14
HADA	292	+++	1.36
Green			
sBADA	457	++	19.55
BADA	378	++	8.63
Atto ₄₈₈ ADA	674	+	21.58
Green-to-yellow			
YADA	489	+++	1.56
Yellow-to-orange			
TADA	517	+	22.00
Cy _{3B} ADA	647	+	6.70
Red			
Atto ₆₁₀ ADA	463	++	3.90

^a FDAs were assigned “+++”, “++”, or “+” if the signal-to-background (S/B) ratio of *E. coli* BW25113 (WT) images was >4 , 2–4, or <2 , respectively.

^b Data represent the fluorescence intensity ratio of *E. coli* *imp4213* BW25113 to *E. coli* BW25113 under the same labeling conditions and microscopy settings.






Fig. 4 Stochastic optical reconstruction microscopy (STORM) of *E. coli* *imp4213* $\Delta 6$ BW25113 cells lacking all L,D-transpeptidases. $\Delta 6$ cells were labeled with Cy_{3B}ADA (A) and TDL (B). Left: Epifluorescence microscopy; right panel: STORM (right). *E. coli* *imp4213* $\Delta 6$ cells were treated with cephalexin for 2 h, washed, and then pulsed with 1 mM Cy_{3B}ADA/TDL for 2 min. Insets in (A) and arrow head highlight a division septum. Scale bar: 2 μ m.

BW25113, a mutant with increased outer membrane permeability.³⁷ Under the same labeling and imaging conditions, FDAA labeling S/B values increased significantly in *E. coli* *imp4213* relative to the parental strain (Fig. S7A†). We represented the ratio of FDAA intensity in *E. coli* *imp4213* over wild-type as the “OM blocking factor” (Table 3). Consistent with displaying lower S/B values in wild-type *E. coli* relative to the other FDAA, sBADA, TADA, and Atto₄₈₈ADA revealed a high blocking factor of ~ 20 , indicating that the OM is a strong permeability barrier for each of these FDAA. On the other hand, HADA and YADA had low blocking factors, suggesting that the OM is highly permeable to these FDAA.

Despite the poor OM permeability to some of the FDAA, optimization of microscope settings can effectively improve S/B of PG labeling to acceptable levels (Fig. S7B†). Moreover, the use of higher FDAA concentrations and/or minimal medium in cell labeling increases FDAA labeling efficiency. In Fig. S7C,† we show TADA and BADA labeling with different FDAA concentrations and culture medium in wild type *E. coli* BW25113. We observed a significant increase in S/B with the use of high FDAA concentrations (3 or 2 mM) compared a lower one (1 mM). An increase was also found when using M9 minimal medium compared to LB. However, additional optimization and control experiments for toxicity effects are strongly recommended when changing experimental conditions.

FDAAs for STORM

Currently, stochastic optical reconstruction microscopy (STORM) and related technologies offer the highest, sub-diffraction-limit, spatial resolution achievable with fluorescence microscopy.³⁸ Atto 488 and Cy_{3B} fluorophores have been reported to have outstanding applicability for direct STORM (dSTORM) and reductive caging STORM (rcSTORM), respectively.^{39,40} Therefore, Atto₄₈₈ADA and Cy_{3B}ADA should enable STORM for cell-wall imaging. Indeed, we conducted rcSTORM visualization of *E. coli* cell wall using Cy_{3B}ADA and the outer-membrane permeable *imp* strain (Fig. 4A). In addition, we note that TADA/TDL also has the potential to be visualized via dSTORM⁴¹ and rcSTORM (Fig. 4B). Further optimization is highly recommended to acquire reliable reconstruction in STORM.

Conclusion and remarks

The synthesis and characterization of the improved FDAA probes described here should be useful when choosing an optimal probe for PG labeling. The new colors yellow (YADA) and red (Atto₆₁₀ADA) that can be spectrally separated from the typical blue (e.g. HADA), green (e.g. BADA), and orange-to-red (e.g. TADA) FDAA will add versatility to the toolset, especially when pairing multiple FDAA with fluorescent protein fusions.



The increased water solubility of the new FDAA compared to older FDAA (e.g. sBADA vs. BADA) will improve S/B ratios of PG labeling in several ways: (1) by allowing pulses with higher FDAA concentrations; (2) by simplifying washes, and (3) by decreasing the non-specific binding to membranes. Similarly, FDAA with improved photostability (e.g. AF₃₅₀DL vs. HADA) or with STORM capabilities (e.g. Cy_{3B}ADA, Atto₄₈₈ADA and TADA) will facilitate PG imaging with increased spatial resolution when combined with super-resolution microscopy techniques.¹⁴

Phototoxicity is a major issue when frequent light exposure is required in an experiment such as time-lapse microscopy. Here, we also introduce Atto₆₁₀ADA, a small, photostable FDAA that is even more red-shifted than the orange-to-red FDAA, TADA. The outer membrane permeability of Atto₆₁₀ADA will allow tracking of PG remodeling in Gram-negative bacteria *via* time-lapse microscopy experiments in far-red region. Finally, our effort to determine the FDAA size dependency for OM permeability (OM blocking factor) not only confirms that FDAA larger than ~500 Da (TADA and Cy_{3B}ADA) are excluded by the OM, but also reveals that other factors might be equally important as size for determining permeability. Specifically, although sBADA (MW: 457 Da) is smaller than the similarly sulfonated FDAA YADA (MW: 489 Da), sBADA is approximately 10 times less permeable than YADA. This discrepancy could result from alternative OM transport mechanisms such as lipid-mediated diffusion.^{42,43}

The modular and simple design of our fluorescent amino acids allows convenient conjugation to a variety of bright and common commercially available organic probes. Such fluorescent amino acids have a variety of potential uses. Fluorescent L-amino acids have found use in peptide synthesis.⁴⁴ More importantly, encoding brighter, red-shifted, yet still relatively small fluorescent amino acids (such as the L-enantiomer of Atto₆₁₀ADA), into proteins could be possible with the availability of new technologies, which in turn would address current issues with utilizing fluorescent protein fusions such as size and maturation.⁴⁵ As we have demonstrated, fluorescent D-amino acids serve as ideal PG probes to elucidate bacterial cell growth and division in high spatiotemporal resolution,^{14,24} or to simply label bacterial cell surfaces for a variety of other applications in diverse bacteria.^{13,16-19,21,22,46} We provide here an improved toolset of FDAA to study *in situ* peptidoglycan synthesis for various purposes that range from identification of modes of cell growth, to peptidoglycan metabolism and turnover, to peptidoglycan–enzyme interactions.

Methods

See compiled ESI.†

Acknowledgements

We thank Josh Vaughan for help on STORM imaging; Xin Meng for help with FDAA synthesis; and David Kysela for help on image processing and analysis. This work was supported by NIH grants 5R01GM113172 to MSV and YVB; R35GM122556 to YVB; a NSF CAREER Award MCB-1149423 to KCH; and Stanford

Center for Systems Biology under Grant P50-GM107615 to KCH. SIM was performed in the Indiana University Light Microscopy Imaging Center supported by S10RR028697-01.

References

- 1 A. Typas, M. Banzhaf, C. A. Gross and W. Vollmer, *Nat. Rev. Microbiol.*, 2011, **10**, 123–136.
- 2 W. Vollmer, D. Blanot and M. A. de Pedro, *FEMS Microbiol. Rev.*, 2008, **32**, 149–167.
- 3 R. A. Daniel and J. Errington, *Cell*, 2003, **113**, 767–776.
- 4 K. Tiyanont, T. Doan, M. B. Lazarus, X. Fang, D. Z. Rudner and S. Walker, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**, 11033–11038.
- 5 T. S. Ursell, J. Nguyen, R. D. Monds, A. Colavin, G. Billings, N. Ouzounov, Z. Gitai, J. W. Shaevitz and K. C. Huang, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, E1025–E1034.
- 6 O. Kocaoglu, R. A. Calvo, L.-T. Sham, L. M. Cozy, B. R. Lanning, S. Francis, M. E. Winkler, D. B. Kearns and E. E. Carlson, *ACS Chem. Biol.*, 2012, **7**, 1746–1753.
- 7 Y. P. Hsu, X. Meng and M. S. VanNieuwenhze, in *Methods in Microbiology*, ed. H. Colin and J. J. Grant, Academic Press, 2016, vol. 43, pp. 3–48.
- 8 E. Kuru, H. V. Hughes, P. J. Brown, E. Hall, S. Tekkam, F. Cava, M. A. de Pedro, Y. V. Brun and M. S. Van Nieuwenhze, *Angew. Chem., Int. Ed.*, 2012, **51**, 12519–12523.
- 9 E. Kuru, S. Tekkam, E. Hall, Y. V. Brun and M. S. Van Nieuwenhze, *Nat. Protoc.*, 2015, **10**, 33–52.
- 10 T. J. Lupoli, H. Tsukamoto, E. H. Doud, T.-S. A. Wang, S. Walker and D. Kahne, *J. Am. Chem. Soc.*, 2011, **133**, 10748–10751.
- 11 Y. Qiao, M. D. Lebar, K. Schirner, K. Schaefer, H. Tsukamoto, D. Kahne and S. Walker, *J. Am. Chem. Soc.*, 2014, **136**, 14678–14681.
- 12 F. Cava, M. A. de Pedro, H. Lam, B. M. Davis and M. K. Waldor, *EMBO J.*, 2011, **30**, 3442–3453.
- 13 T. M. Bartlett, B. P. Bratton, A. Duvshani, A. Miguel, Y. Sheng, N. R. Martin, J. P. Nguyen, A. Persat, S. M. Desmarais, M. S. VanNieuwenhze, K. C. Huang, J. Zhu, J. W. Shaevitz and Z. Gitai, *Cell*, 2017, **168**, 172–185.
- 14 A. W. Bisson Filho, Y.-P. Hsu, G. Squyres, E. Kuru, F. Wu, C. Jukes, Y. Sun, C. Dekker, S. Holden, M. VanNieuwenhze, Y. Brun and E. Garner, *Science*, 2017, **355**, 739–743.
- 15 M. J. Boersma, E. Kuru, J. T. Rittichier, M. S. VanNieuwenhze, Y. V. Brun and M. E. Winkler, *J. Bacteriol.*, 2015, **197**, 3472–3485.
- 16 E. Cserti, S. Rosskopf, Y. W. Chang, S. Eisheuer, L. Selter, J. Shi, C. Regh, U. Koert, G. J. Jensen and M. Thanbichler, *Mol. Microbiol.*, 2017, **103**, 875–895.
- 17 A. K. Fenton, L. E. Mortaj, D. T. Lau, D. Z. Rudner and T. G. Bernhardt, *Nat. Microbiol.*, 2016, **2**, 16237.
- 18 A. Fleurie, C. Lesterlin, S. Manuse, C. Zhao, C. Cluzel, J. P. Lavergne, M. Franz-Wachtel, B. Macek, C. Combet, E. Kuru, M. S. VanNieuwenhze, Y. V. Brun, D. Sherratt and C. Grangeasse, *Nature*, 2014, **516**, 259–262.



19 M. D. Lebar, J. M. May, A. J. Meeske, S. A. Leiman, T. J. Lupoli, H. Tsukamoto, R. Losick, D. Z. Rudner, S. Walker and D. Kahne, *J. Am. Chem. Soc.*, 2014, **136**, 10874–10877.

20 G. Liechti, E. Kuru, M. Packiam, Y.-P. Hsu, S. Tekkam, E. Hall, J. T. Rittichier, M. VanNieuwenhze, Y. V. Brun and A. T. Maurelli, *PLoS Pathog.*, 2016, **12**, e1005590.

21 J. M. Monteiro, P. B. Fernandes, F. Vaz, A. R. Pereira, A. C. Tavares, M. T. Ferreira, P. M. Pereira, H. Veiga, E. Kuru, M. S. VanNieuwenhze, Y. V. Brun, S. R. Filipe and M. G. Pinho, *Nat. Commun.*, 2015, **6**, 8055.

22 D. Morales Angeles, Y. Liu, A. M. Hartman, M. Borisova, A. de Sousa Borges, N. de Kok, K. Beilharz, J. W. Veening, C. Mayer, A. K. Hirsch and D. J. Scheffers, *Mol. Microbiol.*, 2017, **104**, 319–333.

23 M. Pilhofer, K. Aistleitner, J. Biboy, J. Gray, E. Kuru, E. Hall, Y. V. Brun, M. S. VanNieuwenhze, W. Vollmer, M. Horn and G. J. Jensen, *Nat. Commun.*, 2013, **4**, 2856.

24 X. Yang, Z. Lyu, A. Miguel, R. McQuillen, K. K. C. Huang and J. Xiao, *Science*, 2017, **355**, 744–747.

25 J. Zhou and H. Ma, *Chem. Sci.*, 2016, **7**, 6309–6315.

26 L. Li, J. Han, B. Nguyen and K. Burgess, *J. Org. Chem.*, 2008, **73**, 1963–1970.

27 A. Loudet and K. Burgess, *Chem. Rev.*, 2007, **107**, 4891–4932.

28 J. Sangster, *J. Phys. Chem. Ref. Data*, 1989, **18**, 1111–1226.

29 R. A. Scherrer and S. M. Howard, *J. Med. Chem.*, 1977, **20**, 53–58.

30 T. Bernas, M. Zarebski, J. W. Dobrucki and P. R. Cook, *J. Microsc.*, 2004, **215**, 281–296.

31 R. A. Hoebe, C. H. Van Oven, T. W. J. Gadella, P. B. Dhonukshe, C. J. F. Van Noorden and E. M. M. Manders, *Nat. Biotechnol.*, 2007, **25**, 249–253.

32 L. Song, R. P. van Gijlswijk, I. T. Young and H. J. Tanke, *Cytometry*, 1997, **27**, 213–223.

33 R. Dixit and R. Cyr, *Plant J. Cell Mol. Biol.*, 2003, **36**, 280–290.

34 A. H. Delcour, *Biochim. Biophys. Acta, Proteins Proteomics*, 2009, **1794**, 808–816.

35 H. Nikaido and M. Vaara, *Microbiol. Rev.*, 1985, **49**, 1–32.

36 F. Yoshimura and H. Nikaido, *Antimicrob. Agents Chemother.*, 1985, **27**, 84–92.

37 B. A. Sampson, R. Misra and S. A. Benson, *Genetics*, 1989, **122**, 491–501.

38 M. J. Rust, M. Bates and X. Zhuang, *Nat. Methods*, 2006, **3**, 793–796.

39 G. T. Dempsey, J. C. Vaughan, K. H. Chen, M. Bates and X. Zhuang, *Nat. Methods*, 2011, **8**, 1027–1036.

40 J. C. Vaughan, S. Jia and X. Zhuang, *Nat. Methods*, 2012, **9**, 1181–1184.

41 T. Klein, A. Loschberger, S. Proppert, S. Wolter, S. van de Linde and M. Sauer, *Nat. Methods*, 2011, **8**, 7–9.

42 B. Alberts, A. Johnson and J. Lewis, in *Molecular Biology of the Cell*, Garland Science, New York, 4th edn, 2002.

43 G. Camenisch, J. Alsenz, H. van de Waterbeemd and G. Folkers, *Eur. J. Pharm. Sci.*, 1998, **6**, 313–319.

44 A. H. Harkiss and A. Sutherland, *Org. Biomol. Chem.*, 2016, **14**, 8911–8921.

45 J. Luo, R. Uprety, Y. Naro, C. Chou, D. P. Nguyen, J. W. Chin and A. Deiters, *J. Am. Chem. Soc.*, 2014, **136**, 15551–15558.

46 J. M. Fura, D. Kearns and M. M. Pires, *J. Biol. Chem.*, 2015, **290**, 30540–30550.

47 G. McNamara, *McNamara 2007 Fluorophore Data Tables*, Online Source, 2007.

